Showing results (4301-4310 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|March 27, 2019
Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET StudyAngela Lamarca, Joakim Crona, Maxime Ronot, et al.
The Oncologist|March 21, 2019
Care for Smoking Cessation Must Be Proactive and Based on a Combination of Pharmacology and PsychologyAlain Braillon
The Oncologist|March 24, 2019
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and ReviewMeghan E Sise, Harish Seethapathy, Kerry L Reynolds
The Oncologist|February 24, 2019
Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without Helicobacter pylori InfectionWen-Liang Fang, Kuo-Hung Huang, Shih-Ching Chang, et al.
The Oncologist|February 28, 2019
Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's LymphomaCarolina Reyes, Nicole M Engel-Nitz, Stacey DaCosta Byfield, et al.
The Oncologist|September 8, 2019
A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin ToxicitiesYoung Saing Kim, Jun Ho Ji, Sung Yong Oh, et al.
The Oncologist|September 8, 2019
Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy-Refractory Testicular TumorsBijun Lian, Wenhui Zhang, Tiegong Wang, et al.
The Oncologist|September 12, 2019
Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in CanadaJoanna Gotfrit, John J W Shin, Ranjeeta Mallick, et al.
The Oncologist|August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trialDaniel J George, Colin Hessel, Susan Halabi, et al.
The Oncologist|October 4, 2019
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSamuel J Klempner, David Fabrizio, Shalmali Bane, et al.
Pageof 571